Wan-hsuan Hsu

Tainan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 76 publications

Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Response to Letter].

Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Response to Letter].

Journal: Drug design, development and therapy

Published: July 30, 2026

Comparative Risk of Respiratory Virus Infections Among Patients with Asthma Treated with Biologic Therapies.

Comparative Risk of Respiratory Virus Infections Among Patients with Asthma Treated with Biologic Therapies.

Journal: QJM : monthly journal of the Association of Physicians

Published: July 04, 2026

Risk of Lymphoma in Patients with Asthma Treated with Dupilumab Compared with Other Biologic Agents: A Retrospective Cohort Study.

Risk of Lymphoma in Patients with Asthma Treated with Dupilumab Compared with Other Biologic Agents: A Retrospective Cohort Study.

Journal: Chest

Published: April 18, 2026

Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.

Clinical impact of tirzepatide on patients with chronic obstructive pulmonary disease.

Journal: Frontiers in pharmacology

Published: March 25, 2026

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity.

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity.

Journal: Drug design, development and therapy

Published: March 13, 2026

Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study.

Comparative effectiveness of tirzepatide versus thiazolidinedione in adults with MASLD: a propensity score-matched cohort study.

Journal: Frontiers in pharmacology

Published: December 17, 2025

Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.

Clinical benefits of tirzepatide in patients with steatotic liver disease and cardiometabolic dysfunction.

Journal: Communications medicine

Published: October 19, 2025

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study.

Effectiveness of PCSK9 inhibitors versus statins in type 2 diabetes and dyslipidemia: a propensity-matched study.

Journal: Frontiers in endocrinology

Published: September 19, 2025

Response to comments on tirzepatide versus bariatric metabolic surgery in adults with obstructive sleep apnea and obesity.

Response to comments on tirzepatide versus bariatric metabolic surgery in adults with obstructive sleep apnea and obesity.

Journal: Diabetes research and clinical practice

Published: September 02, 2025

Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012-2020: A Retrospective Cohort Study.

Nationwide Incidence, Treatment Pattern, and Prognosis of Primary CNS Lymphoma in Taiwan, 2012-2020: A Retrospective Cohort Study.

Journal: Cancer medicine

Published: September 02, 2025

Obesity and risk of immune-mediated inflammatory diseases: a real-world propensity score-matched cohort study using electronic health records.

Obesity and risk of immune-mediated inflammatory diseases: a real-world propensity score-matched cohort study using electronic health records.

Journal: Scientific reports

Published: August 13, 2025

Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

Comparative effectiveness of empagliflozin versus dapagliflozin in adults with metabolic dysfunction-associated steatotic liver disease.

Journal: Frontiers in endocrinology

Published: July 20, 2025

Showing 1-12 of 76

Last Updated: 09/26/2026